Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Placebo Tablet

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7380   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4,659 result(s) found for: Placebo Tablet. Displaying page 204 of 233.
    «« First « Previous 200  201  202  203  204  205  206  207  208  Next» Last»»
    EudraCT Number: 2021-002350-90 Sponsor Protocol Number: EFC17045 Start Date*: 2022-04-01
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A randomized, double-blind, placebo-controlled, 12 month Phase 3 study to evaluate the effect of venglustat on neuropathic and abdominal pain in male and female participants ≥16 Years of Age with F...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    24.1 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned) DE (Ongoing) DK (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020763-20 Sponsor Protocol Number: 10072DMcA-CS Start Date*: 2010-10-04
    Sponsor Name:National University of Ireland, Galway
    Full Title: Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP 2)
    Medical condition: Acute lung injury
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000619-58 Sponsor Protocol Number: 19CH214 Start Date*: 2021-02-01
    Sponsor Name:CHU SAINT-ETIENNE
    Full Title: A pilot study assessing the feasibility of a randomized controlled trial evaluating aspirin in postpartum women at risk of developing venous thromboembolism Pilot PARTUM Trial: Postpartum Aspirin...
    Medical condition: Post-Partum Venous thromboembolism prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Prematurely Ended) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000555-42 Sponsor Protocol Number: HMR1726D/3001 Start Date*: 2004-11-22
    Sponsor Name:Sanofi-aventis US, Inc
    Full Title: A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the ac...
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) AT (Completed) IT (Completed) GB (Completed) PT (Completed) CZ (Completed) EE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-002261-19 Sponsor Protocol Number: PRN1008-012 Start Date*: 2018-12-12
    Sponsor Name:Principia Biopharma
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus
    Medical condition: pemphigus vulgaris [PV] or pemphigus foliaceus [PF]
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    21.0 100000004858 10057054 Pemphigus foliaceous LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Ongoing) GR (Completed) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000007-17 Sponsor Protocol Number: TAK-875_309 Start Date*: 2013-06-05
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50mg Compared With Placebo as an Add-On to Glimepiride ...
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10063624 Type II diabetes mellitus inadequate control LLT
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 10027433 - Metabolism and nutrition disorders 10029505 Non-insulin-dependent diabetes mellitus LLT
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    14.1 10027433 - Metabolism and nutrition disorders 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000894-56 Sponsor Protocol Number: NAK-06 Start Date*: 2014-02-26
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: A 12-week double-blind, randomised, placebo-controlled, parallel group phase III study, followed by a 4-week randomised withdrawal period to evaluate the efficacy and safety of oral ibodutant 10 mg...
    Medical condition: Irritable bowel syndrome with diarrhoea (IBS-D) in female patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    18.0 100000004856 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) IT (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-002915-23 Sponsor Protocol Number: ARGX-113-1904 Start Date*: 2021-01-25
    Sponsor Name:argenx BV
    Full Title: A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) (ADDRESS)
    Medical condition: Pemphigus Vulgaris or Pemphigus Foliaceus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    20.0 100000004858 10057069 Pemphigus foliaceus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) HU (Completed) BG (Completed) ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007023-26 Sponsor Protocol Number: A3921044 Start Date*: 2009-05-18
    Sponsor Name:Pfizer Inc.
    Full Title: PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE
    Medical condition: CP 690,550 is being studied as a disease modifying antirheumatic drug for the treatment of moderate to severe active rheumatoid arthritis in adults.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GR (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-000132-27 Sponsor Protocol Number: CPR-EFC4492-EN Start Date*: 2006-07-27
    Sponsor Name:sanofi-aventis R&D
    Full Title: Satavaptan Cirrhotic Ascites Treatment Study: a double-blind, randomised, parallel-group comparison of treatment with satavaptan at 5 to 10 mg daily versus placebo on top of conventional treatment ...
    Medical condition: Cirrhotic ascites
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003445 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) BE (Completed) ES (Completed) SE (Completed) HU (Completed) PT (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005325-30 Sponsor Protocol Number: D8180C00015 Start Date*: 2008-04-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-Blind, Placebo Controlled, Multi-Centre, Randomised Study of AZD0530 in Patients with Advanced Ovarian Cancer Sensitive to Platinum-Based Chemotherapy
    Medical condition: advanced ovarian cancer sensitive to platinum based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033129 Ovarian neoplasms malignant (excl germ cell) HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) FR (Completed) DK (Completed) PT (Completed) BG (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-000114-30 Sponsor Protocol Number: ASLAN001-009 Start Date*: 2017-12-14
    Sponsor Name:ASLAN Pharmaceuticals
    Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF VARLITINIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER AS SE...
    Medical condition: Advanced or metastatic biliary tract cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055111 Biliary cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004779-38 Sponsor Protocol Number: CL3-16257-102 Start Date*: 2013-04-16
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Effects of ivabradine on plaque burden, morphology and composition in patients with clinically indicated coronary angiography. A randomised double-blind placebo-controlled international multicentre...
    Medical condition: Coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) SK (Prematurely Ended) BE (Prematurely Ended) DE (Completed) CZ (Completed) HU (Prematurely Ended) PL (Prematurely Ended) SE (Prematurely Ended) NO (Prematurely Ended) DK (Prematurely Ended) GR (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-000381-20 Sponsor Protocol Number: 27820 Start Date*: 2007-11-16
    Sponsor Name:Merck Serono S.A. - Geneva
    Full Title: A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) FR (Completed) GB (Completed) CZ (Completed) BE (Completed) EE (Completed) AT (Completed) PT (Completed) NL (Completed) DE (Completed) DK (Completed) IT (Completed) GR (Completed) LV (Completed) LT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-004977-42 Sponsor Protocol Number: CB-01-11/28 Start Date*: 2017-11-10
    Sponsor Name:Cosmo Technologies Ltd.
    Full Title: A Phase II, multicentre, randomised, double-blind, placebo controlled, proof of concept study of efficacy and safety of Rifamycin SV-MMX® 600 mg tablets administered three or two times daily to pat...
    Medical condition: Diarrhoea-predominant irritable bowel syndrome (IBS-D)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Temporarily Halted) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004429-41 Sponsor Protocol Number: BAY43-9006/12007 Start Date*: 2008-10-03
    Sponsor Name:Bayer Healthcare AG
    Full Title: A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a ...
    Medical condition: The study population will include patients with FIGO stage III or IV ovarian cancer or primary peritoneal cancer who have had extensive debulkment surgery and who have achieved a clinical complete ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052171 Peritoneal carcinoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033164 Ovarian epithelial cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033163 Ovarian epithelial cancer stage III PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) NL (Completed) IT (Completed) ES (Completed) FR (Completed) FI (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003804-37 Sponsor Protocol Number: B7451036 Start Date*: 2019-05-14
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTI CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF 04965842 CO ADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESC...
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) LV (Completed) PL (Completed) GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023048-34 Sponsor Protocol Number: NT-KO-003-2010-01 Start Date*: 2011-04-28
    Sponsor Name:NEUROTEC PHARMA, S.L
    Full Title: Ensayo Clínico Fase IIa, Multicéntrico, Doble Ciego para Evaluar la Eficacia y Seguridad de dosis bajas de Diazoxida oral en el tratamiento de la Esclerosis Múltiple
    Medical condition: Tratamiento de la Esclerosis Múltiple.
    Disease: Version SOC Term Classification Code Term Level
    13 10063399 Esclerosis múltiple remitente-recurrente LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002917-20 Sponsor Protocol Number: JAK116679 Start Date*: 2012-12-11
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled, dose ranging study to evaluate the safety and efficacy of GSK2586184 in patients with chronic plaque psoriasis
    Medical condition: chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050577 Psoriatic plaque LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001211-39 Sponsor Protocol Number: ALK3831-401 Start Date*: 2015-01-27
    Sponsor Name:Alkermes, Inc.
    Full Title: A Phase 2, Efficacy, Safety, and Tolerability Study of ALKS 3831 in Schizophrenia with Alcohol Use Disorder
    Medical condition: Schizophrenia with alcohol use disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 200  201  202  203  204  205  206  207  208  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Aug 13 22:35:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA